Emisphere Technologies, Inc.

Please pardon our appearance as we update
our Web site and refresh product information.

Product Candidates Using The eligen^® Technology
Therapeutic Areas	Development Program	Partner	Status
Cardiovascular	Oral Heparin	Self-developed	Phase III
Cardiovascular	Oral LMWH	Undisclosed	Phase I
Bone Related Disease	Oral Salmon Calcitonin	Novartis Pharma AG¹	Phase III
Bone Related Disease	Oral Recombinant Parathyroid Hormone 1-34	Novartis Pharma AG	Phase I
Diabetes	Oral Insulin	Self-developed	Phase II
Diabetes	Oral GLP	Self-developed	Phase I
Asthma/Allergies	Oral Cromolyn Sodium	Self-developed	Phase I
Growth Disorders	Oral Recombinant Human Growth Hormone	Novartis Pharma AG	Phase I
Anti-Viral	Oral Acyclovir	Undisclosed	Phase I
Obesity	Oral PYY_3-36	Self-developed	Phase I
Oncology	Oral Gallium	Genta, Inc.	Preclinical
Other	Multi Product Research Collaboration	Roche	Preclinical
Other	Feasibility Projects	Undisclosed	Preclinical

¹ Novartis has obtained FDA and EMEA agreement to conduct Phase III trials.